País: Canadà
Idioma: anglès
Font: Health Canada
ORCIPRENALINE SULFATE
AA PHARMA INC
R03CB03
ORCIPRENALINE
2MG
SYRUP
ORCIPRENALINE SULFATE 2MG
ORAL
250ML
Prescription
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0102598001; AHFS:
APPROVED
1997-11-10
_ORCIPRENALINE (Orciprenaline Sulfate Syrup) _ _ _ _ _ _ _ _ _ _ _ _Page 1 of 23 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ORCIPRENALINE Orciprenaline Sulfate Syrup Syrup 2 mg/mL and Oral House Standard Beta-Adrenergic Agonist Bronchodilator AA PHARMA INC. 1165 Creditstone Road, Unit #1 Vaughan, Ontario L4K 4N7 www.aapharma.ca Submission Control Number: 267347 _ _ _ _ Date of Initial Authorization: April 17, 2014 Date of Revision: OCT 11, 2022 _ORCIPRENALINE (Orciprenaline Sulfate Syrup) _ _ _ _ _ _ _ _ _ _ _ _ Page 2 of 23 _ RECENT MAJOR LABEL CHANGES 7 Warnings and Precautions 10/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ................................................................................................................... 4 1.1 Pediatrics .......................................................................................................................... 4 1.2 Geriatrics .......................................................................................................................... 4 2 CONTRAINDICATIONS ...................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ..................................................................................... 5 4.1 Dosing Considerations ...................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ................................................................ 5 4.4 Administration ............................................. Llegiu el document complet